Improving anticoagulation in atrial fibrillation: observational study in three primary care trusts

INTRODUCTION
Atrial fibrillation (AF) is diagnosed in one million people in the UK. Prevalence increases from 0.7% at 55–59 years to 18% >85 years of age, with variation by ethnic group.1,2 A 74-year-old man with AF and no other risk factors has a one in five chance of a stroke and a 40% chance of either a heart attack or stroke within 10 years, estimated using contemporary UK data.3-4 Diabetes and hypertension increase this risk to over 75%. AF accounts for one in eight strokes at all ages and one in three >80 years.5-6

In 2006, the National Institute for Health and Care Excellence (NICE) recommended anticoagulation with warfarin for patients with a CHADS2 score of ≥2, either anticoagulant or antiplatelet treatment for a score of 1, and antiplatelet agents or no treatment for a 0 score.7 Recent European guidelines recommend anticoagulation in patients who score ≥1 with the more accurate CHA2DS2-VASc score; that is anyone age ≥65 years or with at least one risk factor.8,9 For those with a CHA2DS2-VASc score of 0 — people aged <65 years with no other risk factors — no antithrombotic medication is recommended.9 Aspirin is no longer considered an acceptable antithrombotic agent for routine use in AF as it does not effectively reduce stroke and at older ages bleeding may result in net harm.10-11 In 2011, new oral anticoagulant agents [NOAC] were licensed in the UK and supported by NICE as a cost-effective treatment option. These currently include dabigatran, rivaroxaban, and apixaban.12

The problem
Despite the effectiveness of oral anticoagulants in AF, only 50–60% of patients received warfarin or newer anticoagulants.13-15 Fewer older patients with AF are prescribed anticoagulants, and anticoagulant use is poorly related to stroke risk.16 The slope of improvement in anticoagulant use has been static for more than 10 years, improving by 1% per annum to only 50% in 2012.14,17,18 Undertreatment at older ages persists in more recent studies. Three main reasons have been proposed for underuse of anticoagulation; professional therapeutic caution about the balance of risks to benefit, and in particular uncertainty about the role of aspirin; poor quality organisational process including risk stratification; and patient complexity and non-adherence to therapy.1,6,19,20,21 Revision of current NICE guidance recommending antiplatelet agents is likely to advise against routine antiplatelet use and include new oral anticoagulant agents [NOACs].5,7 But translating up-to-date evidence into a step change in improved anticoagulation in primary care will require three main drivers for change. These are supported by...
Theories of behaviour change and practical exemplars. They comprise altering professional beliefs using guidelines and education, making changes in treatment easier for staff and patients with computer decision support and patient recall tools; and motivating practices by publishing comparative performance. Financial incentives may further improve performance but were not used in the current study.

This study describes an intervention using these three components to change clinical practice in all 143 general practices in east London, which serve a population of 800,000 people in three geographically coterminous primary care trusts (PCTs). The study aimed at increasing the proportion of people with AF treated appropriately with anticoagulants and reducing those inappropriately on antiplatelet therapy.

**METHOD**

**Setting**

The study was located in three coterminous inner east London boroughs of Tower Hamlets, Newham, and City and Hackney, and their PCTs, serving the population of 800,000 registered with 143 general practices in the area. The population has some of the highest levels of social deprivation in the UK and half are from ethnic minority groups including large South Asian and African–Caribbean communities.

**Eligibility criteria and intervention**

The programme of improvement was designed and coordinated by the Clinical Effectiveness Group (CEG) funded by the three participating PCTs and based at Queen Mary University of London. Patients were eligible if they had a diagnostic code of atrial fibrillation as specified in the Quality and Outcomes Framework (QOF). The Anticoagulation Programme East London (APEL) was started in April 2011. It aimed at influencing improvement in antithrombotic treatment of AF by altering professional beliefs, influencing clinical processes, and increasing motivation. Changing professional beliefs required provision of new summary clinical guidelines with associated peer education. The new guidance was developed with local stakeholders (GPs, consultants, and prescribing advisers), published by the CEG and sent to all participating practices and made available online. The guidance was also accessible in the routinely used GP clinical record, such that a single ‘click’ on the data entry template opened up the guidance or decision support algorithms. Peer education consisted of a multidisciplinary primary care team meeting in each of the three localities to discuss the evidence and implementation of improvement in AF anticoagulation.

The new guidance was supported with software tools to improve the process of decision making and implementation of care pathways for reviewing and assessing patients with AF and changes in their treatment. Computer software included the APEL tool, which was installed on all practice computers with instruction, to provide an accessible summary of treatment status of individual patients with AF and overall practice performance. This included relevant details such as comorbidities, palliative care, housebound, serious mental illness, alcohol use, falls, bleeding, non-steroidal anti-inflammatory drugs, and the CHA₂DS₂-VASc, CHADS₂, and HAS-BLED scores. Standard data entry templates were used by all practices to ensure fidelity and completeness of coding. ‘Pop-up’ on-screen computer prompts were used by some practices as reminders if patients were on aspirin or no treatment.

In April 2011, a baseline audit was circulated to practices that showed the proportion of patients with AF on anticoagulants and aspirin so that comparisons could be made between identifiable practices in the locality. Financial incentives may further improve performance but were not used in the current study.

**Data collection**

Anonymised data was extracted in May 2013 for 6-monthly periods in each of the 4 years commencing 1 April 2008 to 1 April 2013. The anonymised data were extracted from the electronic patient health record in all patients with AF in...
all general practices with accessible data in the three east London PCTs Newham, Tower Hamlets, and City and Hackney. These data were extracted using EMIS Web on secure N3 terminals. CHA₂DS₂-VASc, CHADS₂ scores were complete on all patients. Prescribing was defined by at least one prescription in the preceding 6 months. The prescribing categories were mutually exclusive: warfarin alone or in combination with an antiplatelet agent; antiplatelet agents (aspirin and/or clopidogrel) did not include warfarin. Any prior comorbidity was recorded and blood pressure or other indices were the latest recorded values. CHA₂DS₂-VASc was calculated from the available data on all patients.

Outcomes
No exclusions were made from this cohort of people with AF. The primary outcome was proportion of patients with AF and CHA₂DS₂-VASc score ≥1 on anticoagulants. The secondary outcome was the proportion on antiplatelet agents.

Analysis
The study conformed to the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) study design recommendations. The funnel plot was compiled using a spreadsheet from the Association of Public Health Observatories. All analyses were undertaken using Stata (version 10), and logistic regression was used to test whether the difference in the annual rate of increase before and after the intervention differed significantly from 0.

RESULTS
Data were available from 139/143 practices in the three inner London Boroughs of Newham, City and Hackney, and Tower Hamlets. Four practices could not contribute because they used a different computer system.

In the period before the intervention April 2008 to April 2011, in all three PCTs combined, the proportion of people with CHA₂DS₂-VASc ≥1 on an anticoagulant increased slowly from 50.8% (1943/3825) to 52.6% (2085/3964), a non-significant increase of 2.2% in 3 years; test to determine whether the increase differed from zero, P = 0.184.

After the intervention which started in April 2011, the proportion of people on anticoagulants increased from 52.6% (2085/3964) in April 2011 to 59.8% (2492/4168) by April 2013, an increase of 7.2% in 2 years. The difference in slope of the trends was 1.63, 95% confidence interval (CI) = 1.32 to 1.94, P < 0.001. In people aged ≥80 years or over, anticoagulant prescription 2009 to 2013 increased by 9.0% (from 45.3% to 54.3%), whereas for people <80 years it increased by 6.6% (from 52.6% to 59.2%). These differences in increase between age groups were not significant (P = 0.598).

The proportion of people with CHA₂DS₂-VASc ≥1 on antiplatelets showed little change in the period 2008 to 2011, 38.8% to 37.7% (P = 0.458). From April 2011 there was a decline in antiplatelet use from 37.7% to 30.3%; a reduction of 7.4%. The difference in trend slope was −1.68 (95% CI = −2.21 to −1.16, P < 0.001).

The proportion of people with AF on neither anticoagulants nor antiplatelet agents was 10.3% in April 2008 and 9.9% in April 2013, and did not change significantly (Figure 1). These trends in anticoagulation in people with CHA₂DS₂-VASc ≥1 showed similarly significant improvement (P < 0.001) in
all three PCTs. City and Hackney 53.5% (748/1398) to 60.0% (882/147), difference 6.5%; Tower Hamlets 53.9% (622/1155) to 60.9% (745/1224), difference 7.0%; and Newham 50.7% (715/1411) to 58.9% (867/1473), difference 8.1%.

Individual practices showed substantial variation in prescribing of anticoagulants. Small numbers in small practices result in wide random variation. Figure 2 shows a funnel plot of the AF register size against proportion on anticoagulants in each practice, with 2 and 3 SD limits. Most practices fall within the 2 SD limit with six of 139 practices outside the lower 2 SD limit, and three outside the lower 3 SD limit. Of the 139 practices, 10.8% (15/139) prescribed 40% or fewer patients with anticoagulants and 16.5% (23/139) prescribed 70% or more anticoagulants. Total AF register size increased by 108 in the 2 years prior to the intervention and almost doubled to 204 in the 2 years after the intervention.

**DISCUSSION**

**Summary**

The present study showed a threefold increase in the rate of improvement in anticoagulation in people with CHA2DS2-VASc ≥1 on anticoagulation increasing from 52.6% to 59.8%; 7.2% over 2 years in comparison with an increase of 2.2% over the preceding 3 years. Considerable variation persisted, much of it accountable by random variation in smaller practices. One in 10 practices had <40% or fewer patients with AF on anticoagulants, and one in six achieved ≥70% on anticoagulation. Overdispersion, with more than expected numbers of practices outside the lower 95% confidence limits indicate that systematic factors need to be considered, and that there is scope for further improvement in all practices to achieve ≥80% on anticoagulants.

**Strengths and limitations**

This study covers three entire local health economies in some of the most socially-diverse and disadvantaged boroughs in the UK, indicating the feasibility of improvement even in challenging local circumstances. No patients were excluded from this study.

The interventions — guidance, education, software enhancements, and evaluative feedback — are potentially available within every CCG and are generalisable. The initial involvement and cooperation of all stakeholders — haematologists, cardiologists, community and hospital prescribing advisers, PCT managers, GPs and their practice teams — were important components of the intervention, requiring a series of meetings and consultations to ensure that the strategy and content are agreeable to all participants. Since the end of the programme, financial incentives have been added to anticoagulation targets to support further improvement in two of the CCGs.

Since 2007 there have been national initiatives to improve anticoagulation, including financial incentives as part of the QOF and GRASP-AF, which made little impact in the period 2008–2011. The promotion of antiplatelet agents including aspirin, in line with the 2006 NICE guidance, may also have hindered improvements in anticoagulation rates before 2011. It was not possible to access data from a control primary care trust for the period under consideration. Therefore, it is, not possible to establish the extent to which changes in QOF 2012, when anticoagulation was separated from aspirin as a payment target, and the changed clinical consensus on aspirin in 2012, contributed to changes in 2012/13. The changes started, however, at the time of the intervention a year earlier.

Anticoagulant monitoring also improved. In Tower Hamlets, City and Hackney from 2009, and Newham from 2010, local practice- and pharmacy-based monitoring was established, with local community schemes for 30–60% of people on anticoagulants. This may have assisted the take-up and acceptability of anticoagulation with warfarin. Local prescribing advisers in Tower Hamlets have also included anticoagulant prescribing in incentive schemes since 2012.

Almost all practices in inner east London use a single web-enabled computer system (EMIS), which permits access to...
standard data entry templates, prompts, software tools such as the APEL tool, and evaluative reporting, and this was of benefit to this project. This functionality is replicable across all computer systems but may take more time to implement where CCGs use a diversity of systems. The CEG coordinated the programme with all three CCGs, providing leadership, stakeholder engagement, and a coherent plan including evaluation and this may be a ‘local’ factor in improvement. Clinical leads in each CCG were active local ‘champions’ promoting clear objectives and actions.

The intervention was complex and limited to only 2 years. It is difficult to estimate which components were responsible for the improvement observed and whether the rate of improvement will be sustained.

**Comparison with existing literature**
The UK General Practice Research Database showed an increase in the proportion on anticoagulants in patients aged ≥80 years from 25% in 2000 to 37% in 2009, and from 54% to 55% in those aged 60–69 years in this period.\(^2,19\)

Attempts since 2007 by the NHS Improvement programme using the GRASP-AF software tool to improve anticoagulation had limited success.\(^26\)

About one-quarter of practices in England UK participated, and anticoagulation increased from 49.3% to 54.7% over the period 2009–2012. In 2012, however, 36% remained on antiplatelet therapy alone and 11% on neither.\(^21\)

Since 2007, the QOF financially incentivised antiplatelet and anticoagulant treatment, although until 2013 the impact on anticoagulation could not be disaggregated.\(^26\)

Despite these initiatives, improvement remained static at 1% per annum; the proportions of people with CHADS, ≥2 on anticoagulants were 49.7% in 2007 and 53% in 2010.\(^4\)

The most recent national data 2012/13 from the QOF show that 65.1% of patients with AF received anticoagulants.\(^39\)

**Implications for research and practice**
Checking and validation of people with AF is likely to have identified miscoding or resolved AF, particularly in those on no treatment or antiplatelet agents. The ‘cleaning’ of AF registers to remove patients who have left or been miscoded may have further contributed to denominator accuracy, increasing the proportion of the target group on anticoagulants, and this may be responsible for some of the observed effect. Despite culling of incorrect entries, new AF diagnoses almost doubled and was a wider consequence of the focus on AF management.

Anticoagulation is only one aspect of the patient pathway for AF from ascertainment to treatment, and raised blood pressure control, smoking, and statins also make a substantial impact on cardiovascular event reduction. Better access to monitoring and support for patient information and their continuing treatment can also improve patient experience and quality of life. Improvement in the current undertreatment of AF, however, is likely to have the single greatest impact and even in older patients with complex needs, ≥80% can be anticoagulated.\(^40\)

Wide discrepancy in anticoagulation rates between practices remain with considerable room for further improvement. The 2012/13 QOF showed that although 29% of GP practices in London attained ≥70% on anticoagulants without exception, one-fifth had <55% of patients on anticoagulants.

CCG averages in London ranged from 56.2% in Islington to 71.2% in Sutton, with City and Hackney 69.7%, Tower Hamlets 64.7%, and Newham 69.7%.\(^23\)

This study demonstrates that increasing anticoagulation by 3.5% per annum to 10% within 3 years and a comparable reduction in antiplatelets agents is a feasible task. To indicate the likely benefit of this improvement, assumptions were made about the stroke risk in those patients newly started on anticoagulants. Anticoagulation reduces the risk of stroke by 64% compared with placebo.\(^41\)

According to the BAFTA trial, 50% lower incidence of stroke and severe haemorrhagic episodes could be expected in patients on warfarin compared with aspirin.\(^11\)

If the clinical improvement observed in the study area was applied to all 1 million people with AF known to GP practices in the UK, (assuming an annual risk of stroke of 4% in people ≥75 years, 2% 65–74 years, and 1% <65 years), then a reduction of stroke by approximately 1600 and heavy bleeding by 200 every year could be expected. Increased ascertainment of new cases of AF as a result of the programme and reduction of inappropriate dual use of aspirin with anticoagulants could further reduce stroke and bleeding. Reducing stroke nationally by 1600 per annum amounts to six per CCG at a 5-year healthcare cost of £150 000.\(^42\)

This would be offset by a 1-year cost of anticoagulant treatment of £120 000, making initiatives to increase anticoagulation by 10% highly cost-effective.

The cost of these basic tools for improvement is modest in comparison...
with the cost of not taking action.42 The entire cost of the programme — producing and circulating guidelines, the educational sessions, the development and installation of the APEL tool in all practices, the data extraction, reports and their circulation — was approximately £15,000 per CCG (£300 per practice), although this utilised a pre-existing infrastructure of academic support and web-connected record systems. This does not take account of the time that many clinicians gave for guideline development, APEL tool testing, and staff training, and the costs incurred by GPs from cleaning registers, reviewing patients, and altering treatment, which often required haematology referrals.

To maintain this programme beyond 2 years, there is a recurrent annual cost of approximately £100 per practice, £5000 per CCG per annum to update guidelines and computer software, and produce and distribute evaluative reports.

This intervention was effective in increasing the number of appropriately treated patients with AF; however, the untreated proportion remained high, with considerable variability between practices. Additional investment by CCGs in supportive programmes is required to increase the slope of improvement and attain 80% levels of anticoagulation without inappropriate delay.

Addendum
This programme has since received support from University College London Partners, Academic Health Science Network to support improvement in anticoagulation across 21 CCGs with a population of 6 million.
REFERENCES


